Hrt Financial LP Tricida, Inc. Transaction History

Hrt Financial LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.14 - $12.49 $38,656 - $3.45 Million	276,121 Added 1838.6%	291,139 $44,000
Q3 2022 Nov 14, 2022	SELL	$8.51 - $13.6 $276,617 - $442,068	-32,505 Reduced 68.4%	15,018 $157,000
Q2 2022 Aug 12, 2022	BUY	$7.31 - $11.85 $347,393 - $563,147	47,523 New	47,523 $460,000
Q4 2021 Feb 14, 2022	SELL	$4.19 - $9.56 $293,794 - $670,328	-70,118 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.56 - $4.64 $33,506 - $43,671	-9,412 Reduced 11.83%	70,118 $325,000
Q2 2021 Aug 16, 2021	BUY	$3.95 - $5.41 $314,143 - $430,257	79,530 New	79,530 $343,000
Q1 2021 May 17, 2021	SELL	$4.52 - $7.8 $176,971 - $305,393	-39,153 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$4.37 - $9.46 $171,098 - $370,387	39,153 New	39,153 $276,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.